An Open-Label Multicenter Study Administering Lapatinib and Capecitabine in Women With Advanced or MEtastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Nov 2018
At a glance
- Drugs Capecitabine (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; Novartis Pharmaceuticals
- 10 Oct 2018 Planned End Date changed from 31 Dec 2016 to 10 Apr 2020.
- 28 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.
- 03 May 2015 Planned End Date changed from 1 Jun 2014 to 1 Dec 2015, as reported by Clinicaltrials.gov.